US5770198A
(en)
*
|
1988-05-18 |
1998-06-23 |
The Research Foundation Of The State Of New York |
Platelet-specific chimeric 7E3 immunoglobulin
|
US5169930A
(en)
*
|
1990-01-05 |
1992-12-08 |
La Jolla Cancer Research Foundation |
Fibronectin receptor
|
US7150974B1
(en)
|
1991-04-05 |
2006-12-19 |
The General Hospital Corporation |
Parathyroid hormone receptor binding method
|
US7132260B2
(en)
*
|
1991-04-05 |
2006-11-07 |
The General Hospital Corporation |
DNA encoding parathyroid hormone receptor
|
US5494806A
(en)
*
|
1991-04-05 |
1996-02-27 |
The General Hospital Corporation |
DNA and vectors encoding the parathyroid hormone receptor, transformed cells, and recombinant production of PTHR proteins and peptides
|
WO1994015958A2
(en)
*
|
1993-01-08 |
1994-07-21 |
Tanabe Seiyaku Co., Ltd. |
Peptide inhibitors of cell adhesion
|
AU6235294A
(en)
*
|
1993-02-02 |
1994-08-29 |
Scripps Research Institute, The |
Methods for producing polypeptide binding sites
|
US6500924B1
(en)
|
1996-05-31 |
2002-12-31 |
The Scripps Research Institute |
Methods and compositions useful for inhibition of angiogenesis
|
US5753230A
(en)
|
1994-03-18 |
1998-05-19 |
The Scripps Research Institute |
Methods and compositions useful for inhibition of angiogenesis
|
US6056958A
(en)
*
|
1994-12-09 |
2000-05-02 |
Dupont Pharmaceuticals |
Method of treatment of arterial and venous thromboembolic disorders
|
DK0719859T3
(en)
*
|
1994-12-20 |
2003-10-20 |
Merck Patent Gmbh |
Anti-alpha V integrin monoclonal antibody
|
US5817768A
(en)
*
|
1995-06-07 |
1998-10-06 |
The New York Blood Center, Inc. |
Monospecific antibodies against a subunit of fibrinogen
|
AU4134497A
(en)
*
|
1996-09-03 |
1998-03-26 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-integrin alpha3 antibody complexes
|
ES2321991T3
(en)
*
|
1996-12-09 |
2009-06-15 |
Merck Patent Gmbh |
ADHESION RECEIVER ALFAVBET3 RECOMBINANT SOLUBLE.
|
US6596850B1
(en)
|
1998-01-30 |
2003-07-22 |
Ixsys, Incorporated |
Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
|
US20010011125A1
(en)
*
|
1997-01-30 |
2001-08-02 |
William D. Huse |
Anti-alpha v beta 3 recombinant human antibodies, nucleic acids encoding same and methods of use
|
US6590079B2
(en)
*
|
1997-01-30 |
2003-07-08 |
Ixsys, Incorporated |
Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
|
CA2284518A1
(en)
*
|
1997-03-12 |
1998-09-17 |
Smithkline Beecham Corporation |
Anti-alphabeta3 humanized monoclonal antibodies
|
AU6954498A
(en)
*
|
1997-04-11 |
1998-11-11 |
G.D. Searle & Co. |
Methods for using antagonistic anti-avb3 integrin antibodies
|
ES2187954T3
(en)
*
|
1997-04-11 |
2003-06-16 |
Searle & Co |
ANTI-INTEGRINE ANTIBODIES AVB3 ANTAGONISTS.
|
US6210904B1
(en)
*
|
1997-10-14 |
2001-04-03 |
Merck & Co., Inc. |
Anticoagulant test
|
DE19828068C2
(en)
*
|
1998-06-24 |
2003-12-18 |
Peter Dietsch |
Specific inhibitor of osteoclast bone resorption
|
JP2002522504A
(en)
*
|
1998-08-13 |
2002-07-23 |
ジー・ディー・サール・アンド・カンパニー |
Multivalent avb3 and metastasis-related receptor ligand
|
CA2351452A1
(en)
*
|
1998-12-04 |
2000-06-15 |
Novartis Ag |
Methods and compositions useful for targeting activated vitronectin receptor .alpha.v.beta.3
|
US6833373B1
(en)
|
1998-12-23 |
2004-12-21 |
G.D. Searle & Co. |
Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
|
US7049140B1
(en)
|
1999-04-29 |
2006-05-23 |
Vanderbilt University |
X-ray guided drug delivery
|
US6159443A
(en)
*
|
1999-04-29 |
2000-12-12 |
Vanderbilt University |
X-ray guided drug delivery
|
US6531580B1
(en)
|
1999-06-24 |
2003-03-11 |
Ixsys, Inc. |
Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
|
US6037176A
(en)
*
|
1999-06-25 |
2000-03-14 |
Isis Pharmaceuticals Inc. |
Antisense inhibition of integrin beta 3 expression
|
DE60042700D1
(en)
*
|
1999-09-08 |
2009-09-17 |
Markus Albers |
INTEGRIN-MEDICINED MEDICINAL TARGET DIRECTION
|
AU783063B2
(en)
*
|
1999-10-28 |
2005-09-22 |
Seyedhossein Aharinejad |
Use of CSF-1 inhibitors
|
US7740841B1
(en)
*
|
2000-01-28 |
2010-06-22 |
Sunnybrook Health Science Center |
Therapeutic method for reducing angiogenesis
|
ES2260234T3
(en)
*
|
2000-05-12 |
2006-11-01 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. |
USE OF INHIBITORS OF THE PLACENTARY GROWTH FACTOR FOR THE TREATMENT OF PATHOLOGICAL ANGIOGENESIS, PATHOLOGICAL ARTERIOGENESIS, INFLAMMATION, TUMORAL FORMATION AND / OR VASCULAR LOSS.
|
US7163681B2
(en)
|
2000-08-07 |
2007-01-16 |
Centocor, Inc. |
Anti-integrin antibodies, compositions, methods and uses
|
US7288390B2
(en)
|
2000-08-07 |
2007-10-30 |
Centocor, Inc. |
Anti-dual integrin antibodies, compositions, methods and uses
|
US7220824B1
(en)
|
2000-08-28 |
2007-05-22 |
Bayer Aktiengesellschaft |
Integrin-mediated drug targeting
|
EP1219305A1
(en)
*
|
2000-12-27 |
2002-07-03 |
Bayer Aktiengesellschaft |
Conjugates of integrin receptor antagonists and a cytostatic agent having specifically cleavable linking units
|
MXPA03007878A
(en)
*
|
2001-03-02 |
2004-07-08 |
Medimmune Inc |
Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists.
|
US7906102B2
(en)
|
2001-10-03 |
2011-03-15 |
Vanderbilt University |
Ligands to radiation-induced molecules
|
US7306925B2
(en)
|
2001-11-09 |
2007-12-11 |
Vanderbilt University |
Phage antibodies to radiation-inducible neoantigens
|
US8658773B2
(en)
|
2011-05-02 |
2014-02-25 |
Immunomedics, Inc. |
Ultrafiltration concentration of allotype selected antibodies for small-volume administration
|
AU2003213682C1
(en)
*
|
2002-03-04 |
2008-06-12 |
Medimmune, Inc. |
Methods of preventing or treating disorders by administering an integrin alphavbeta3 antagonist in combination with an HMG-CoA reductase inhibitor or a bisphosphonate
|
EP1487492A4
(en)
*
|
2002-03-04 |
2008-10-01 |
Medimmune Inc |
The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
|
JP2005535572A
(en)
*
|
2002-04-12 |
2005-11-24 |
メディミューン,インコーポレーテッド |
Recombinant anti-interleukin-9 antibody
|
US20050186204A1
(en)
*
|
2002-06-28 |
2005-08-25 |
Peter Carmeliet |
Use of antibodies against FLT-1 for the treatment of osteoporosis
|
AU2003251729A1
(en)
*
|
2002-06-28 |
2004-01-19 |
K.U.Leuven Research & Development |
Use of antibodies against flt-1 for the treatment of osteoporosis
|
AU2004207002A1
(en)
*
|
2003-01-30 |
2004-08-12 |
Medimmune, Inc. |
Uses of integrin alphavbeta3 antagonists
|
KR101224235B1
(en)
|
2003-04-11 |
2013-01-25 |
메디뮨 엘엘씨 |
Recombinant IL-9 Antibodies and Uses Thereof
|
US20070185077A1
(en)
*
|
2003-07-15 |
2007-08-09 |
Washington University |
Methods of treating, preventing and inhibiting cancer metastasis and tumor formation
|
US7271245B2
(en)
*
|
2004-02-13 |
2007-09-18 |
The Scripps Research Institute |
Methods and compositions for inhibition of metastasis
|
US7351739B2
(en)
*
|
2004-04-30 |
2008-04-01 |
Wellgen, Inc. |
Bioactive compounds and methods of uses thereof
|
DE602005020137D1
(en)
*
|
2004-05-07 |
2010-05-06 |
Univ North Carolina |
METHOD FOR REINFORCING OR INHIBITING THE INSULINARY GROWTH FACTOR-I
|
US8187595B2
(en)
|
2004-05-07 |
2012-05-29 |
The University Of North Carolina At Chapel Hill |
Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I
|
US20060051345A1
(en)
|
2004-06-04 |
2006-03-09 |
Genentech, Inc. |
Method for treating multiple sclerosis
|
CA2585717A1
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune Inc. |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
PT1869085E
(en)
*
|
2005-03-24 |
2012-06-01 |
Vlaams Interuniv Inst Biotech Vzw |
Novel anti-plgf antibody
|
US7867490B2
(en)
*
|
2005-06-30 |
2011-01-11 |
Vib Vzw |
Treatment of liver cirrhosis and its complications
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
WO2008011216A2
(en)
*
|
2006-05-16 |
2008-01-24 |
Pro-Pharmaceuticals, Inc. |
Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
|
WO2008008373A2
(en)
|
2006-07-11 |
2008-01-17 |
Arubor Corp |
Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
|
US7862813B2
(en)
*
|
2006-07-29 |
2011-01-04 |
Bjork Jr Robert Lamar |
Bi-specific monoclonal antibody (specific for both CD3 and CD11b) therapeutic drug
|
JP2010500360A
(en)
|
2006-08-10 |
2010-01-07 |
アルボア コーポレーション |
Local therapy of lower respiratory inflammatory diseases with inflammatory cytokine inhibitors
|
TW201014605A
(en)
|
2008-09-16 |
2010-04-16 |
Genentech Inc |
Methods for treating progressive multiple sclerosis
|
JP5522717B2
(en)
*
|
2008-09-19 |
2014-06-18 |
国立大学法人佐賀大学 |
Atopic dermatitis detection method and prophylactic / therapeutic agent screening method
|
MX2011003428A
(en)
|
2008-10-02 |
2011-07-29 |
Vib Vzw |
Inhibition of plgf to treat philadelphia chromosome positive leukemia.
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
CN102265158A
(en)
*
|
2008-12-23 |
2011-11-30 |
通用电气健康护理有限公司 |
Application of 99mtc peptide-based compound as a bone marrow imaging agent
|
EP3243527B1
(en)
|
2009-02-13 |
2019-06-05 |
Immunomedics, Inc. |
Immunoconjugates with an intracellularly-cleavable linkage
|
CA2774260C
(en)
|
2009-09-16 |
2018-10-09 |
Immunomedics, Inc. |
Class i anti-cea antibodies and uses thereof
|
EP2506881B1
(en)
|
2009-12-02 |
2024-03-06 |
Immunomedics, Inc. |
Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
|
WO2013079713A1
(en)
|
2011-12-01 |
2013-06-06 |
Thrombogenics Nv |
Improving trabeculectomy outcome
|
WO2013101771A2
(en)
|
2011-12-30 |
2013-07-04 |
Genentech, Inc. |
Compositions and method for treating autoimmune diseases
|
WO2013116287A1
(en)
|
2012-01-31 |
2013-08-08 |
Genentech, Inc. |
Anti-ig-e m1' antibodies and methods using same
|
US9315567B2
(en)
|
2012-08-14 |
2016-04-19 |
Ibc Pharmaceuticals, Inc. |
T-cell redirecting bispecific antibodies for treatment of disease
|
MX2015002465A
(en)
*
|
2012-08-31 |
2015-11-06 |
Univ North Carolina |
Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor 1 (igf-1).
|
HRP20220399T1
(en)
|
2012-12-13 |
2022-05-13 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
|
WO2014130648A1
(en)
|
2013-02-20 |
2014-08-28 |
Galectin Therapeutics, Inc. |
Method for treatment of pulmonary fibrosis
|
MX2016010683A
(en)
|
2014-02-21 |
2017-05-11 |
Ibc Pharmaceuticals Inc |
Disease therapy by inducing immune response to trop-2 expressing cells.
|
CN106029098A
(en)
|
2014-02-25 |
2016-10-12 |
免疫医疗公司 |
Humanized RFB4 anti-CD22 antibody
|
US9580495B2
(en)
|
2014-06-24 |
2017-02-28 |
Immunomedics, Inc. |
Anti-histone therapy for vascular necrosis in severe glomerulonephritis
|
US10449261B2
(en)
|
2014-07-24 |
2019-10-22 |
Washington University |
Compositions targeting radiation-induced molecules and methods of use thereof
|
CN106999517A
(en)
|
2014-10-07 |
2017-08-01 |
免疫医疗公司 |
The new adjuvant purposes of antibody drug conjugate
|
EP3286224A4
(en)
|
2015-04-22 |
2018-11-14 |
Immunomedics, Inc. |
Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
|
WO2016210108A1
(en)
|
2015-06-25 |
2016-12-29 |
Immunomedics, Inc. |
Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
SI3316885T1
(en)
|
2015-07-01 |
2021-09-30 |
Immunomedics, Inc. |
Antibody-sn-38 immunoconjugates with a cl2a linker
|
IL293708A
(en)
|
2015-10-06 |
2022-08-01 |
Genentech Inc |
Method for treating multiple sclerosis
|
EP3207937A1
(en)
|
2016-02-17 |
2017-08-23 |
Royal College of Surgeons in Ireland |
A method of treating or preventing sepsis
|
KR102101561B1
(en)
*
|
2018-07-25 |
2020-04-20 |
가톨릭대학교 산학협력단 |
Angiogenesis target constrast medium and a method for producing the same
|
WO2021015336A1
(en)
*
|
2019-07-24 |
2021-01-28 |
가톨릭대학교 산학협력단 |
SINGLE DOMAIN ANTIBODY TARGETING αVβ3 INTEGRIN
|
EP4281079A1
(en)
|
2021-01-22 |
2023-11-29 |
Royal College of Surgeons in Ireland |
Treatment of coronavirus
|
EP4342497A1
(en)
|
2021-05-10 |
2024-03-27 |
Kawasaki Institute of Industrial Promotion |
Antibody having reduced binding affinity for antigen
|